METHOD OF TREATING PATIENTS WITH CHRONIC VIRAL HEPATITIS TYPE C, GENOTYPE 3a Russian patent published in 2010 - IPC A61K31/422 A61K38/20 A61K38/21 A61K31/685 A61K31/51 A61P1/16 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to virology, and can be used in treatment of chronic viral hepatitis type C, genotype 3a. That is ensured by subcutaneous introduction of Ronkoleukin in dosage 0.5 mg once a week for 24-32 weeks with underlying administration vitamin B complex, hepatoprotectors and the antiviral therapy including intramuscular introduction of IFN-α in dosage 3 million IU 3 times week and per os administration of Ribavirin in a daily dose 800 mg.

EFFECT: method ensures a stable viral response due to intensified T-cell immunity link by restored synthesis of endogenous IL-2 with activated CD-4 and CD-8 lymphocytes, compensated deficiency of IL-2 production by mononuclear cells, restored and increased functional activity of target cells of endogenous IL-2: NK-cells, T-lymphocytes helpers, monocytes.

2 tbl, 2 ex